Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficient prevalence estimation and infected sample identification with group testing for SARS-CoV-2

Brian Cleary, View ORCID ProfileJames A. Hay, Brendan Blumenstiel, Stacey Gabriel, Aviv Regev, Michael J. Mina
doi: https://doi.org/10.1101/2020.05.01.20086801
Brian Cleary
1Broad Institute of MIT and Harvard, Cambridge, MA 02142 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcleary@broadinstitute.org aregev@broadinstitute.org mmina@hsph.harvard.edu
James A. Hay
2Centre for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James A. Hay
Brendan Blumenstiel
1Broad Institute of MIT and Harvard, Cambridge, MA 02142 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacey Gabriel
1Broad Institute of MIT and Harvard, Cambridge, MA 02142 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aviv Regev
3Klarman Cell Observatory, Broad Institute of MIT and Harvard
4Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142 USA
5Howard Hughes Medical Institute, Chevy Chase, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcleary@broadinstitute.org aregev@broadinstitute.org mmina@hsph.harvard.edu
Michael J. Mina
1Broad Institute of MIT and Harvard, Cambridge, MA 02142 USA
2Centre for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
6Department of Immunology and Infectious Diseases, Harvard School of Public Health
7Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcleary@broadinstitute.org aregev@broadinstitute.org mmina@hsph.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The ongoing pandemic of SARS-CoV-2, a novel coronavirus, caused over 3 million reported cases of coronavirus disease 2019 (COVID-19) and 200,000 reported deaths between December 2019 and April 20201. Cases and deaths will increase as the virus continues its global march outward. In the absence of effective pharmaceutical interventions or a vaccine, wide-spread virological screening is required to inform where restrictive isolation measures should be targeted and when they can be lifted2–6. However, limitations on testing capacity have restricted the ability of governments and institutions to identify individual clinical cases, appropriately measure community prevalence, and mitigate transmission. Group testing offers a way to increase efficiency, by combining samples and testing a small number of pools7–9. Here, we evaluate the effectiveness of group testing designs for individual identification or prevalence estimation of SARS-CoV-2 infection when testing capacity is limited. To do this, we developed mathematical models for epidemic spread, incorporating empirically measured individual-level viral kinetics to simulate changing viral loads in a large population over the course of an epidemic. We used these to construct representative populations and assess pooling strategies for community screening, accounting for variability in viral load samples, dilution effects, changing prevalence and resource constraints. We confirmed our group testing framework through pooled tests on de-identified human nasopharyngeal specimens with viral loads representative of the larger population. We show that group testing designs can both accurately estimate overall prevalence using a small number of measurements and substantially increase the identification rate of infected individuals in resource-limited settings.

Competing Interest Statement

A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Asimov, and Neogene Therapeutics.

Funding Statement

Work was supported by the Merkin Institute Fellowship at the Broad Institute of MIT and Harvard (B.C.), by the National Institute of General Medical Sciences (#U54GM088558; JAH and MJM); and by an NIH DP5 grant (MJM).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Raw data generated in this study are available in Extended Data Tables 3 and 5.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 06, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficient prevalence estimation and infected sample identification with group testing for SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficient prevalence estimation and infected sample identification with group testing for SARS-CoV-2
Brian Cleary, James A. Hay, Brendan Blumenstiel, Stacey Gabriel, Aviv Regev, Michael J. Mina
medRxiv 2020.05.01.20086801; doi: https://doi.org/10.1101/2020.05.01.20086801
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Efficient prevalence estimation and infected sample identification with group testing for SARS-CoV-2
Brian Cleary, James A. Hay, Brendan Blumenstiel, Stacey Gabriel, Aviv Regev, Michael J. Mina
medRxiv 2020.05.01.20086801; doi: https://doi.org/10.1101/2020.05.01.20086801

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9003)
  • Forensic Medicine (4)
  • Gastroenterology (421)
  • Genetic and Genomic Medicine (1962)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1330)
  • Health Policy (662)
  • Health Systems and Quality Improvement (520)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10826)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1837)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (356)
  • Occupational and Environmental Health (470)
  • Oncology (1003)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (183)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (582)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4133)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (82)